Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 11/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164924 | 0.90 | SERPINE1 (0.44) | SERPINE1LMNAPOLBMAPTPGR | |
| SCHEMBL5557531 | 0.90 | SERPINE1 (0.44) | SERPINE1LMNAPOLBMAPT | |
| SCHEMBL6439266 | 0.87 | SERPINE1 (0.42) | SERPINE1SIRT6LMNAPOLBMAPT | |
| SCHEMBL5563843 | 0.87 | SERPINE1 (0.44) | SERPINE1LMNAPOLBMAPTTDP1 | |
| SCHEMBL27517225 | 0.86 | SERPINE1 (0.45) | SERPINE1SIRT6POLBWDR5MAPT | |
| SCHEMBL7148217 | 0.86 | WDR5 (0.37) | LMNAPOLBWDR5MAPTTDP1 | |
| SCHEMBL6469844 | 0.83 | LMNA (0.37) | LMNAPOLBWDR5MAPTRXFP1 | |
| SCHEMBL7139831 | 0.79 | GRM5 (0.39) | LMNAWDR5MAPTTDP1 | |
| SCHEMBL5557383 | 0.78 | LMNA (0.43) | LMNAPOLBMAPTPGRCYP3A4 | |
| SCHEMBL5556419 | 0.78 | LMNA (0.43) | LMNAPOLBPGRCYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | SERPINE1 695/4885SIRT6 1219/4885LMNA 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.